Cargando…

Obesity as a Risk Factor in the Appearance of Haematomas Caused by Low-Molecular-Weight Heparin: A Cross-Sectional Study

Thromboembolic disease (TED) is an important health problem in Europe due to its high morbimortality. Pharmacological prevention is achieved with low-molecular-weight heparin (LMWH), among other strategies, which are supported by a high degree of evidence in the scientific literature. According to i...

Descripción completa

Detalles Bibliográficos
Autor principal:	Díaz-González, Candelaria de la Merced
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204504/ https://www.ncbi.nlm.nih.gov/pubmed/37218948 http://dx.doi.org/10.3390/nursrep13020067

Ejemplares similares

Spontaneous and Severe Haematomas in Patients with COVID-19 on Low- Molecular-Weight Heparin for Paroxysmal Atrial Fibrillation
por: Mazzitelli, Maria, et al.
Publicado: (2020)

Heparin: Haematoma: case report
Publicado: (2022)

Heparin: Iliopsoas haematoma: case report
Publicado: (2021)

Heparin: Psoas haematoma: case report
Publicado: (2022)

Heparin/nafamostat: Bleeding and subcutaneous haematoma: case report
Publicado: (2022)

Corticosteroid/heparin: Rectus sheath haematoma: case report
Publicado: (2022)

Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)

Enoxaparin sodium/heparin/tenecteplase: Haematoma: 6 case reports
Publicado: (2022)

Influence of Hospital Environmental Variables on Thermometric Measurements and Level of Concordance: A Cross-Sectional Descriptive Study
por: Díaz-González, Candelaria de la Merced, et al.
Publicado: (2023)

Heparin/low molecular weight heparins: Thrombocytopenia: 7 case reports
Publicado: (2021)

Influence of Skin Phototype on the Level of Pain Perceived by Patients Receiving Enoxaparin: A Cross-Sectional Study
por: Díaz-González, Candelaria de la Merced, et al.
Publicado: (2022)

Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001)

Heparin/thrombomodulin-α: Bleeding leading to multiple haematomas: case report
Publicado: (2021)

Enoxaparin-sodium/heparin: Rectus sheath haematoma: 2 case reports
Publicado: (2021)

Effect of heparin and low-molecular weight heparin on serum potassium and sodium levels
por: Bengalorkar, Girish M., et al.
Publicado: (2011)

Comparison of Low-Molecular-Weight Heparins Prepared From Ovine Heparins With Enoxaparin
por: Chen, Jianle, et al.
Publicado: (2019)

Heparin: Spontaneous soft tissue haematoma and retroperitoneal haemorrhage: 2 case reports
Publicado: (2021)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

The Effect of Low Molecular Weight Heparins on Fracture Healing
por: Kapetanakis, Stylianos, et al.
Publicado: (2015)

Low-molecular weight heparin infusion as anticoagulation for haemodialysis
por: Wong, Steve Siu-Man, et al.
Publicado: (2016)

COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis
por: Perna, Alessandra F., et al.
Publicado: (2020)

Management of intentional overdose of low-molecular-weight heparin
por: Lu, Clara, et al.
Publicado: (2022)

A meta-analysis of bridging anticoagulation between low molecular weight heparin and heparin
por: Tao, Ende, et al.
Publicado: (2020)

Low-Molecular-Weight Heparin and Unfractionated Heparin Decrease Th-1, 2, and 17 Expressions
por: Huang, Jing-Ning, et al.
Publicado: (2014)

Is the Incidence Trend of Heparin-Induced Thrombocytopenia Decreased by the Increased Use of Low-Molecular-Weight-Heparin?
por: Al-Eidan, Fahad A S
Publicado: (2015)

Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients
por: Volteas, Panagiotis, et al.
Publicado: (2022)

Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease
por: Shute, Janis Kay
Publicado: (2023)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Update on the clinical use of the low-molecular-weight heparin, parnaparin
por: Camporese, Giuseppe, et al.
Publicado: (2009)

The potential benefits of low-molecular-weight heparins in cancer patients
por: Robert, Francisco
Publicado: (2010)

Diffuse alveolar hemorrhage associated with low molecular weight heparin
por: Hayashi, Shinichi, et al.
Publicado: (2013)

Low molecular weight heparin use in unexplained recurrent miscarriage
por: Yuksel, Halide, et al.
Publicado: (2014)

Use of low-molecular-weight heparin in COVID-19 patients
por: Kow, Chia Siang, et al.
Publicado: (2020)

Low molecular weight heparin in COVID-19: benefits and concerns
por: Makarem, Adham, et al.
Publicado: (2023)

Changes in Coagulation and Fibrinolysis in Post-Cesarean Section Parturients Treated With Low Molecular Weight Heparin
por: Liu, Ziwei, et al.
Publicado: (2020)

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005)

Use of low-molecular-weight heparin in severe paraquat poisoning: a case report
por: Montoya-Giraldo, Maria A., et al.
Publicado: (2020)

The efficacy and safety of low-molecular-weight heparin and unfractionated heparin in the treatment of cerebral venous sinus thrombosis
por: Afshari, Daryoush, et al.
Publicado: (2015)

Measuring the anticoagulant effect of low molecular weight heparins in the critically ill
por: Crowther, Mark, et al.
Publicado: (2006)

Monitoring of treatment with low molecular weight heparins using viscoelastic devices
por: Schött, U, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1n6ps5qt67g2l7iucpgn9us23e